



## **Bee Vectoring Technologies Receives Key US Patent Approvals**

**MISSISSAUGA, ON – MARCH 1, 2016 – Bee Vectoring Technologies International Inc.** (the “Company” or “BVT”) (TSXV: BEE) is pleased to announce that it has received a notice of application approval from the U.S patent and trademark office for two of its three pending applications.

BVT has actively sought three patents in 40 countries around the world relating to its system for biological control of pathogens in crops and delivery system using bees. The notice of approval has been received from the U.S patent and trademark office on the two following applications:

- Application 14/483,345 relates to a formulation comprising a particulate calcium silicate and can contain *clonostachys rosea* for treating plants (Vectorite™). BVT’s Vectorite™ is a proprietary mixture of products that allows the inoculant to get attached to a bee’s hairy legs and body as it walks through the tray on their way out of the hive. The Vectorite allows for delivery of BVT inoculums either individually or together with other bio-controls and crop controls.
- Application 14/110,323 relates to specialist apparatus for the treatment of plants (inoculum dispenser and tray). The BVT inoculum dispenser system is incorporated into the lid of commercial bumble bee hives. In the dispenser is a removable tray that contains, in powder form, the inoculant crop control and a mixture of products (Vectorite™) that allows the bees to effectively pick up the product on their way out of the hive.

The third application, which relates to an active ingredient used in the BVT system, remains within the official process pending approval. This application was filed at a later date than the other two now approved.

BVT CEO, Michael Collinson said “Gaining approval on patent applications within the US is notoriously difficult and securing these represents another major step for BVT in the implementation of its global growth strategy. We will continue our pursuit of full patents in approximately 40 additional countries around the world. The delivery system is now protected by these patents and the system is being commercialized with other bio controls”.

### **About [Bee Vectoring Technologies International Inc.](#)**

BVT has developed and owns patent-pending bee vectoring technology (consisting of a proprietary tray dispenser containing a unique carrier agent) that is designed to harmlessly utilize commercially reared bumblebees as natural delivery mechanisms for a variety of powdered mixtures comprised of organic compounds that inhibit or eliminate common crop diseases, while at the same time stimulating and enhancing the same crops. This unique and proprietary process facilitates a targeted delivery of crop controls using the simple process of bee pollination to replace traditional crop spraying, resulting in better yield, organic product and less impact on the environment without the use of water or disruptions to labour.

Additional information can be viewed at the Company’s website [www.beevt.com](http://www.beevt.com) .

**On Behalf of the Board of Directors of Bee Vectoring Technologies International Inc.,**

*“Michael Collinson”*  
President & CEO

**For further information, please contact:**

Michael Collinson, President & CEO  
Tel: 647-660-5119  
[marketing@beevt.com](mailto:marketing@beevt.com)

**For media enquiries or interviews, please contact:**

Josh Stanbury | [josh@sjspr.co.uk](mailto:josh@sjspr.co.uk) | T. 416-628-7441

*Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.*

*This press release contains certain "forward-looking statements" that involve known and unknown risks and uncertainties. All statements in this press release, other than statements of historical fact, that address events or developments that BVT expects to occur, are forward-looking statements. Forward-looking statements in this press release include, but are not limited to, statements with respect to: the protection of the BVT system, the pursuit of additional patents internationally, the commercialization of the BVT system with other bio controls, BVT'S future plans and technologies, including the timing of such plans and technologies. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential", "indicate" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although BVT believes that the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include continued availability of capital, financing and required resources (such as human resources, equipment and/or other capital resources), and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of BVT'S management on the date the statements are made. BVT undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change, except as required by law.*